Fully enrolled Cohorts 1 and 2 of AX-0811 Phase 1 trial; initial target engagement data expected in early January 2027 Full AX-0810 Phase 1 dataset, including Cohort 3 and follow-up data, and new AX-0811 preclinical proof-of-concept data to be presented in December 2026 Multiple clinical milestones expected in H1 of 2027, including initiation of pediatric biliary atresia IIT, initial AX-0422 patient data in MPS I Hurler syndrome, and advancement of AX-2911 into the clinic for MASH IIT Ended Q3 2026 with € 103 million cash and cash equivalents, supporting runway into mid-2028 LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.